World Biological Therapy: Oligodendroglioma - Pipeline Review, H2 2011

• Publication date: August 2011

This report provides information on the therapeutic development for Oligodendroglioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oligodendroglioma. '' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured...

This report provides information on the therapeutic development for Oligodendroglioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oligodendroglioma. '' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of the Research

- A snapshot of the global therapeutic scenario for Oligodendroglioma.
- A review of the Oligodendroglioma products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Oligodendroglioma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Oligodendroglioma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Biological Therapy Industry

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global March kets Direct Report Coverage 7
Oligodendroglioma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Oligodendroglioma 9
Oligodendroglioma Therapeutics under Development by Firms 11
Oligodendroglioma Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Oligodendroglioma Therapeutics - Products under Development by Firms 18
Oligodendroglioma Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Oligodendroglioma Therapeutics Development 21
AstraZeneca PLC 21
Tocagen Inc 21
Oligodendroglioma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
AZD8055 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CPT-11 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Tandutinib + Bevacizumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Tandutinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Gleevec - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
procarbazine hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Temozolomide + Busulfan + Thiotepa - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Temozolomide + Busulfan + Thiotepa - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Lomustine + Procarbazine + Vincristine + Radiation Therapy - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 40
Temozolomide + Radiation Therapy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Topotecan hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Filgrastim + Sargramostim + Cyclophosphamide + Thiotepa + Peripheral Blood Stem Cell Transplantation/Autologous Bone March row Transplantation - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Filgrastim + Sargramostim + Cyclophosphamide + Thiotepa + Peripheral Blood Stem Cell Transplantation/Autologous Bone March row Transplantation - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
carmustine + mercaptopurine + streptozocin - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 48
Peptide vaccine + Poly-ICLC - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Peptide vaccine + Poly-ICLC - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Bendamustine Hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Temozolomide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Bevacizumab + Radiation Therapy - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
RAD001 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Aminolevulinic acid - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Procarbazine + Lomustine + Vincristine + Radiation Therapy - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Temozolomide + Radiation Therapy - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Alloreactive Cytotoxic T Lymphocytes + Interleukin-2 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Autologous Tumor Cell Vaccine + Sargramostim + Muromonab-CD3 + Aldesleukin + Radiation Therapy - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 61
Toca 511 + Toca FC - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
AMD3100 + Avastin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BIBF 1120 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Oligodendroglioma Therapeutics – Drug Profile Updates 67
Oligodendroglioma Therapeutics - Discontinued Products 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 70
Contact Us 70
Disclaimer 70

List of Tables

Number of Products Under Development for Oligodendroglioma, H2 2011 9
Products under Development for Oligodendroglioma – Comparative Analysis, H2 2011 10
Number of Products under Development by Firms, H2 2011 11
Number of Products under Investigation by Universities/Institutes, H2 2011 13
Number of Products under Investigation by Universities/Institutes, H2 2011 14
Comparative Analysis by Late Stage Development, H2 2011 15
Comparative Analysis by Mid Clinical Stage Development, H2 2011 16
Comparative Analysis by Early Clinical Stage Development, H2 2011 17
Products under Development by Firms, H2 2011 18
Products under Investigation by Universities/Institutes, H2 2011 19
Products under Investigation by Universities/Institutes, H2 2011 20
AstraZeneca PLC, 2011 21
Tocagen Inc, 2011 21
Assessment by Monotherapy Products, H2 2011 22
Assessment by Combination Products 23
Assessment by Stage and Route of Administration, H2 2011 25
Assessment by Molecule Type, H2 2011 27
Oligodendroglioma Therapeutics – Drug Profile Updates 67
Discontinued Products 68

List of Figures

Number of Products under Development for Oligodendroglioma, H2 2011 9
Products under Development for Oligodendroglioma – Comparative Analysis, H2 2011 10
Products under Development by Firms, H2 2011 11
Products under Investigation by Universities/Institutes, H2 2011 12
Late Stage Products, H2 2011 15
Mid Clinical Stage Products, H2 2011 16
Early Clinical Stage Products, H2 2011 17
Assessment by Monotherapy Products, H2 2011 22
Assessment by Combination Products, H2 2011 23
Assessment by Route of Administration, H2 2011 24
Assessment by Stage and Route of Administration, H2 2011 25
Assessment by Molecule Type, H2 2011 26
Assessment by Stage and Molecule Type, H2 2011 27